These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 23649961)

  • 1. Use of new oral anticoagulants in antiphospholipid syndrome.
    Arachchillage DJ; Cohen H
    Curr Rheumatol Rep; 2013 Jun; 15(6):331. PubMed ID: 23649961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term benefits of preventing venous thromboembolic events.
    Cohen AT
    Curr Med Res Opin; 2012 Jun; 28(6):877-89. PubMed ID: 22533680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New oral anticoagulants for the treatment of venous thromboembolism.
    Agnelli G; Becattini C; Franco L
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
    Schneeweiss S; Gagne JJ; Patrick AR; Choudhry NK; Avorn J
    Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):480-6. PubMed ID: 22787066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
    Kakkos SK; Kirkilesis GI; Tsolakis IA
    Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):565-75. PubMed ID: 24951377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disadvantages of VKA and requirements for novel anticoagulants.
    Shameem R; Ansell J
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):103-14. PubMed ID: 23953899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Thromboembolic prophylaxis 2011: is warfarin on the wane?].
    Di Pasquale G; Riva L
    G Ital Cardiol (Rome); 2011 Sep; 12(9):556-65. PubMed ID: 21892216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of the new oral anticoagulants: opportunities and challenges.
    Yeh CH; Hogg K; Weitz JI
    Arterioscler Thromb Vasc Biol; 2015 May; 35(5):1056-65. PubMed ID: 25792448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
    Gómez-Outes A; Terleira-Fernández AI; Lecumberri R; Suárez-Gea ML; Vargas-Castrillón E
    Thromb Res; 2014 Oct; 134(4):774-82. PubMed ID: 25037495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re: 'Re. Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of VTE: A Systematic Review and Meta-analysis of Phase III Trials'.
    Kakkos SK; Kirkilesis GI; Tsolakis IA
    Eur J Vasc Endovasc Surg; 2015 Jul; 50(1):127. PubMed ID: 25882231
    [No Abstract]   [Full Text] [Related]  

  • 13. New oral anticoagulants in the management of venous thromboembolism: a major advance?
    Sciascia S; Hunt BJ
    Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):487-8. PubMed ID: 25150440
    [No Abstract]   [Full Text] [Related]  

  • 14. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel anticoagulants vs warfarin for stroke prevention in atrial fibrillation.
    Turagam MK; Velagapudi P; Bongu NR; Kocheril AG
    Cardiovasc Hematol Disord Drug Targets; 2014; 14(1):79-86. PubMed ID: 25088126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re: 'Kakkos et al. Efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials'.
    Spanos K; Giannoukas AD
    Eur J Vasc Endovasc Surg; 2015 Mar; 49(3):353. PubMed ID: 25556084
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: 'Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials'- Key Learning Points for Surgeons.
    Hurst KV; Lee R; Milosevic I; Handa A
    Eur J Vasc Endovasc Surg; 2015 Jul; 50(1):126-7. PubMed ID: 25933476
    [No Abstract]   [Full Text] [Related]  

  • 18. Response to 'Re: Kakkos et al. Efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials'.
    Kakkos SK; Kirkilesis GI; Tsolakis IA
    Eur J Vasc Endovasc Surg; 2015 Mar; 49(3):353-4. PubMed ID: 25556083
    [No Abstract]   [Full Text] [Related]  

  • 19. Switching between oral anticoagulants.
    Strasser KM; Qasem A; Madhusudhana S
    Hosp Pract (1995); 2014 Aug; 42(3):68-74. PubMed ID: 25255408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical management of new oral anticoagulants after total hip or total knee arthroplasty.
    Klauser W; Dütsch M
    Musculoskelet Surg; 2013 Dec; 97(3):189-97. PubMed ID: 24249360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.